BRCA2 Protein

Medical cannabis and its effect on oncological outcomes in patients with ovarian cancer treated with PARP inhibitors
Shira Peleg Hasson, Eliya Shachar, Miriam R Brezis, Akram Saad, Bar Toledano, Nadav Michaan, Ido Laskov, Dan Grisaru, Jeffrey Goldstein, Amir Nutman, Tamar Safra

International Journal of Gynecologic Cancer Apr 2024, 34 (4) 559-565; DOI: 10.1136/ijgc-2023-004953
Management challenges in low-grade serous ovarian cancer with a BRCA mutation
Luisa Sanchez-Lorenzo, Lidia Sancho, Teresa Iscar, Rachel Grisham, Luis Chiva

International Journal of Gynecologic Cancer Apr 2024, 34 (4) 631-636; DOI: 10.1136/ijgc-2023-005240
Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with BRCA mutated advanced high grade serous ovarian cancer: 10 year survival analysis
Soyoun Rachel Kim, Ashna Parbhakar, Xuan Li, Marcus Q Bernardini, Liat Hogen, Taymaa May

International Journal of Gynecologic Cancer Mar 2024, ijgc-2023-005065; DOI: 10.1136/ijgc-2023-005065
Attitude of BRCA1/2 mutation carriers towards surgical risk reduction for breast, ovarian and uterine cancer: still much to be done
Chen Nahshon, Yakir Segev, Meirav Schmidt, Ofer Lavie

International Journal of Gynecologic Cancer Feb 2024, 34 (2) 260-266; DOI: 10.1136/ijgc-2023-004801
Pitfalls in identifying intronic germline pathogenic variants by comprehensive cancer genomic profiling: technical limitations or biased clinical/diagnostic utility?
Maria De Bonis, Camilla Nero, Giovanni Scambia, Nicola Normanno, Angelo Minucci

International Journal of Gynecologic Cancer Mar 2024, ijgc-2024-005382; DOI: 10.1136/ijgc-2024-005382
Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: association with treatment outcomes
Zena Alizzi, Sayeh Saravi, Saira Khalique, Thirza McDonald, Emmanouil Karteris, Marcia Hall

International Journal of Gynecologic Cancer Sep 2023, 33 (9) 1427-1433; DOI: 10.1136/ijgc-2023-004483
Systemic therapy de-escalation in advanced ovarian cancer: a new era on the horizon?
Giuseppe Caruso, Robert L Coleman, Giovanni Aletti, Francesco Multinu, Andrea Botticelli, Innocenza Palaia, William Cliby, Nicoletta Colombo

International Journal of Gynecologic Cancer Sep 2023, 33 (9) 1448-1457; DOI: 10.1136/ijgc-2023-004740
Correspondence on ‘Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors’ by Musacchio et al
Fatma Ferda Verit, Fuat Demirkiran

International Journal of Gynecologic Cancer Dec 2023, 33 (12) 1988; DOI: 10.1136/ijgc-2023-004943
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors
Lucia Musacchio, Serena Boccia, Claudia Marchetti, Angelo Minucci, Floriana Camarda, Chiara Cassani, Jole Ventriglia, Vanda Salutari, Viola Ghizzoni, Elena Giudice, Maria Teresa Perri, Maria Vittoria Carbone, Caterina Ricci, Sandro Pignata, Anna Fagotti, Giovanni Scambia, Domenica Lorusso

International Journal of Gynecologic Cancer Jun 2023, 33 (6) 922-928; DOI: 10.1136/ijgc-2022-003903
Epithelial ovarian cancer and brain metastases: might the BRCA status, PARP inhibitor administration, and surgical treatment impact the survival?
Carolina Maria Sassu, Claudia Marchetti, Giorgia Russo, Angelo Minucci, Serena Maria Boccia, Alberto Benato, Camilla Nero, Alessia Piermattei, Pier Paolo Mattogno, Diana Giannarelli, Gabriella Ferrandina, Alessandro Olivi, Anna Fagotti, Giovanni Scambia

International Journal of Gynecologic Cancer Jan 2024, 34 (1) 88-98; DOI: 10.1136/ijgc-2023-004980

Main menu

BRCA2 Protein

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

BRCA2 Protein

Pages